AP306 is a first-in-class pan-phosphate transporter inhibitor in development for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) receiving dialysis
Alebund grants exclusive rights to develop, manufacture, and commercialize AP306 outside Greater China to R1 Therapeutics, a newly launched company backed by leading global kidney care providers and life sciences strategic and venture capital investors
The collaboration includes potential milestone payments of up to low triple-digit millions of U.S. dollars and tiered royalties in the low double-digit percentage range based on net sales of AP306 in the licensed territory
Alebund holds a substantial non-dilutive equity interest in R1, with the opportunity to participate in future commercial upside through dividends
Shanghai, China – March 17, 2026 – Alebund Pharmaceuticals (“Alebund” or the “Company”), a leading renal-focused biopharmaceutical company, today announced that it has entered into licensing and equity agreements (the “Agreements”) with R1 Therapeutics, Inc. (“R1”). R1 is a newly launched clinical-stage biotechnology company that recently completed an oversubscribed Series A financing of $77.5M. R1 is backed by major global kidney care providers, DaVita, one of the largest kidney care providers globally, and U.S. Renal Care, the largest privately held dialysis provider in the United States and a syndicate of leading global venture capital investors.
Continue reading Alebund Pharmaceuticals Announces Collaboration and License Agreement with R1 Therapeutics for AP306
